Clinical Trials Browser

Chickenpox, Neuroblastoma, Osteosarcoma

NCT04897321 2026-04-15

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

CNSDermatologicGastrointestinalGenitourinarySarcoma

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 1/2 Recruiting

58 enrolled

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT01822652 2026-04-06

GRAIN

Phase 1 Active not recruiting

11 enrolled

CNS

Neuroblastoma, Recurrence

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

18 enrolled

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT06186401 2026-03-16

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Phase 1 Recruiting

20 enrolled

CNS

Glioblastoma

NCT07358260 2026-01-22

B7-H3.CD28Z.CART in Solid Tumors

Phase 1 Not yet recruiting

40 enrolled

CNS

Neuroblastoma

NCT04539366 2025-11-03

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Phase 1 Suspended

67 enrolled

CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT04530487 2025-06-29

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Phase 2 Terminated

1 enrolled 7 charts

CNSSarcoma

Neuroblastoma, Rhabdomyosarcoma, Neuroectodermal Tumors, Primitive, Peripheral, Neurofibrosarcoma, Desmoplastic Small Round Cell Tumor

NCT04521946 2024-10-26

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Phase 1 Withdrawn

CNS

Choroid Plexus Carcinoma, Brain Neoplasms, Ependymoma, Glioma, Medulloblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT02774291 2023-08-04

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Phase EARLY_PHASE1 Terminated

3 enrolled 6 charts

CNS

Brain Neoplasms, Neoplasm Metastasis

NCT05303727 2022-07-01

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Phase 2 Not yet recruiting

64 enrolled

CNS

Neuroblastoma

NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Phase 2 Completed

11 enrolled 12 charts

BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

NCT00698009 2020-09-24

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

Phase 2 Terminated

1 enrolled 2 charts

CNS

Neuroblastoma

NCT01454596 2019-08-21

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Phase 1/2 Completed

18 enrolled 25 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT00801931 2019-03-27

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Phase 1/2 Terminated

1 enrolled 8 charts

CNSClassical hematologyLymphoidOther hematologic neoplasm

Anemia, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Neuroblastoma

NCT00670410 2016-06-24

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Phase 1 Terminated

15 enrolled

CNS

Neuroblastoma

NCT00874315 2015-10-16

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Phase 2 Withdrawn

CNS

Neuroblastoma, Recurrence

NCT00084695 2014-01-10

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

Phase 2 Unknown

25 enrolled

CNSClassical hematologyLymphoidMyeloidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Fanconi Anemia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Recurrence, Sarcoma, Leukemia, Myeloid, Chronic-Phase, Neuroectodermal Tumors, Primitive, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Dendritic Cell Sarcoma, Interdigitating

Clinical Trials

VEGAS

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

GRAIN

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

B7-H3.CD28Z.CART in Solid Tumors

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases